There are currently no regulations for residents disposing of sharps/needles at home
Insider Tip: BPC-157 should not be used by people with diagnosed or suspected cancer, as its potential to promote new blood vessel formation could cause cancer to grow or spread.19 Whos a candidate for BPC-157 peptide therapy
Tirzepatide, as the first GLP-1/GIP dual receptor agonist, demonstrated greater benefits in blood glucose control and weight reduction compared with GLP-1 single receptor agonists like semaglutide and dulaglutide, induced by the combined activation of both receptors.23,26 The latest results from the SURMOUNT-5 trial, published in May 2025, indicate that in obese individuals without diabetes, tirzepatide led to greater reductions in both weight and waist circumference compared with semaglutide
J Cell Physiol 232:6977
One of the primary ways GLP-1 medications support weight loss is through a process called delayed gastric emptying
PlexusDx maintains no affiliate deal, partnership, or paid tie with Noom or its parent company
